
    
      The first period (12 weeks double blind period) will aim at demonstrating the efficacy and
      safety of BF2.649 by verifying whether the results of BF2.649 are superior to those of
      placebo.

      The aim of the second period (open label extension phase) will be to assess the long-term
      tolerance, as well as the maintenance of the BF2.649 efficacy.
    
  